These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34763450)

  • 1. Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure.
    Zhou L; Yang Y; Han W
    Ann Palliat Med; 2021 Oct; 10(10):10887-10895. PubMed ID: 34763450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF
    J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol of BEYOND trial: Clinical BEnefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhYthm cONtrol of atrial fibrillation in patients with diabetes mellitus.
    Lee K; Lee SK; Lee J; Jeon BK; Kim TH; Yu HT; Lee JM; Park JK; Baek YS; Kim DH; Shim J; Joung B; Lee MH; Pak HN; Park J
    PLoS One; 2023; 18(1):e0280359. PubMed ID: 36652465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.
    Eroglu TE; Coronel R; Souverein PC
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):289-295. PubMed ID: 38520149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):1977-1986. PubMed ID: 36881169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
    Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
    Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
    Correale M; Antohi EL; Inciardi RM; Mazzeo P; Coiro S; Ishihara S; Petroni R; Monitillo F; Leone M; Triggiani M; Sarwar CMS; Dungen HD; Talha KM; Brunetti ND; Butler J; Nodari S;
    ESC Heart Fail; 2023 Jun; 10(3):2066-2073. PubMed ID: 36924023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.
    Zheng S; Lai Y; Jiang C; He L; Zhao Z; Li W; Tang R; Sang C; Long D; Du X; Ma C; Dong J
    Pacing Clin Electrophysiol; 2024 Jan; 47(1):58-65. PubMed ID: 38010824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M; Dietrich JW; Nauck MA; Lim S
    Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.
    Talha KM; Butler J; Greene SJ; Aggarwal R; Anker SD; Claggett BL; Docherty KF; Solomon SD; McMurray JJV; Januzzi JL; Vaduganathan M; Fonarow GC
    Eur J Heart Fail; 2023 Jul; 25(7):999-1009. PubMed ID: 37062865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure.
    Shrestha DB; Budhathoki P; Sedhai YR; Karki P; Gurung S; Raut S; Damonte JI; Del Buono MG; Mojadidi MK; Elgendy IY; Patel T; Patel NK
    J Cardiovasc Pharmacol; 2021 Oct; 78(4):501-514. PubMed ID: 34269700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
    Filippatos G; Farmakis D; Butler J; Zannad F; Ferreira JP; Ofstad AP; Iwata T; Brueckmann M; Pocock SJ; Packer M; Anker SD;
    Eur J Heart Fail; 2023 Jul; 25(7):970-977. PubMed ID: 37062866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X; Xu S; Li J; Tong N
    Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.